Skin, Bone, Blood

Price Rationale

Final judgement centers Skin, Bone, Blood near, but not mechanically above, its exact-token 90 ETH SuperRare sale from 2021-05-15. The comparable-sales and USD/ETH-cycle appraisers both land at 95 ETH, the cultural appraiser is modestly higher at 105 ETH, and the liquidity appraiser is lower at 72 ETH because there is no live bid, no ask, no OTC history, no grail flag, and no token-specific candidate set. I reject the 72 ETH liquidity mark as too punitive for a 2019 SuperRare XCOPY 1/1 with a clean 90 ETH exact sale and Flamingo DAO custody, but I also reject a full cultural push above 100 ETH because the supplied packet gives no current market depth or grail/canon flag. A 94 ETH fair value gives primary weight to the direct 90 ETH execution, allows only a small scarcity and age premium, and uses a wide 68-125 ETH bid/ask range to reflect negotiated 1/1 liquidity.

What Caps The Price

A materially higher value would overread a single 2021 cycle sale and the broad XCOPY scarcity narrative. The source has no current ask, no current best bid, no OTC sale, no grail flag, no grail reason names, and candidateCount is 0. Stronger 2019 XCOPY works with fresher 2024-2025 evidence can support higher marks, but Skin, Bone, Blood lacks the supplied public-standing and recent-demand evidence needed to price in that upper tier.

What Supports The Price

A much lower value would ignore direct exact-token evidence: this work cleared onchain for 90 ETH / $352,794.60 on SuperRare in 2021 after its 0.5 ETH 2019 primary-era sale. It is an early 2019 XCOPY one-of-one with single-token supply and Flamingo DAO ownership, and multiple appraisers independently found the 90-105 ETH zone more representative than a forced-liquidity discount. The absent live bid lowers confidence and bid support, but it does not erase the prior 90 ETH market-clearing sale.